Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.00
- Piotroski Score 6.00
- Grade Overweight
- Symbol (PFE)
- Company Pfizer Inc.
- Price $27.46
- Changes Percentage (0.37%)
- Change $0.1
- Day Low $27.35
- Day High $27.59
- Year High $31.54
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
- Last Earnings 10/09/2024
- Ex-Dividend for 5/16 Dividend 11/08/2024
- Dividend Payable 12/02/2024
- Today N/A
- Next Earnings (Estimated) 01/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $46.00
- High Stock Price Target $70.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.05
- Trailing P/E Ratio -571.6
- Forward P/E Ratio -571.6
- P/E Growth -571.6
- Net Income $2.12 B
Income Statement
Quarterly
Annual
Latest News of PFE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Pfizer (NYSE:PFE) a High-Yielding Dividend Stock Worth Buying?
High-yielding dividend stocks can often be risky, but Pfizer stands out as a solid choice with its 5.9% yield. The company's strong third-quarter results and cost-saving initiatives make it a promisin...
By Yahoo! Finance | 1 week ago -
Pfizer Inc. (PFE): Among the Worst Performing Blue Chip Stocks in 2024
The article discusses the poor performance of Pfizer Inc. in 2024 compared to other blue-chip stocks. Despite its past success with the COVID-19 vaccine, Pfizer's stock has been under pressure due to ...
By Yahoo! Finance | 2 weeks ago -
Goldman Sachs: Pfizer Inc. (NYSE:PFE) Is A Stock With High Consensus ROE
Goldman Sachs' report highlights stocks with high consensus ROE, ranking Pfizer Inc. 27th. Market dynamics are shifting due to interest rate changes, impacting economic conditions and stock performanc...
By Yahoo! Finance | 2 weeks ago
